That will be a bitter pill for Martin Shkreli to swallow.
The so-called “pharm bro” and one-time CEO of Turing Pharmaceuticals became the target of a social media and publicity furor in 2015, when the company inflated the price of Daraprim—a drug used to treat cancer and HIV patients felled by a deadly parasitic infection—by about 4,000 percent from $13.50 to $750 per pill. (Shkreli’s since been charged with securities fraud and is currently awaiting trial.)
In the interim, a group of upstart high school chemistry students from Australia heard about the Shkreli/Daraprim story and were inspired to act. The group of 11 students, all 16- and 17-year-olds, created their own pyrimethamine, the active ingredient in Daraprim, in Sydney Grammar School’s laboratory. The drug, which treats a parasitic infection called toxoplasmosis, was made on a small scale—about 3.7 grams—for $20 total (that’s about $2 per pill).
After the public outcry, Turing Pharmaceuticals eventually lowered the cost of the anti-parasitic drug by 50 percent for hospitals, but the costs have remained the same for pharmacies.
Daraprim is primarily used to treat patients with compromised immune systems, particularly HIV-positive pregnant women and patients undergoing chemotherapy.
Learn how the students did it in the video below.
Find more info here.
This article was featured in the InsideHook newsletter. Sign up now.